1. Introduction {#s1}
===============

Non-inferiority of transcatheter aortic valve implantation (TAVI) by comparison to surgical aortic valve replacement (AVR) is demonstrated in high-risk patients in terms of survival and major morbidity.[@b1]--[@b10] A recent meta-analysis of 17 separate TAVI *vs*. AVR studies corroborated this in all-cause mortality analyses.[@b11] Previous studies also support consistent improvements in functional New York Heart Association (NYHA) Class,[@b12]--[@b18] and heart failure specific quality of life (QOL) in patients undergoing TAVI procedures.[@b13],[@b17],[@b18] However, findings with generic QOL measures, which are those reflecting day-to-day functioning,[@b19] are less conclusive.

With respect to previous QOL studies, neither the transfemoral nor transapical intervention group in the PARTNER study showed significant improvements on the EuroQOL at one year.[@b13] By contrast, Bekeredjian, *et al*.[@b16] showed significant improvement at six months in all generic Short Form-36 (SF-36) QOL domains with the greatest gains evident in physical functioning. Krane, *et al*.[@b14] also reported improvement in the majority of SF-36 QOL domains, however, no significant improvement was found for three others, whereas emotional-role functioning decreased. These findings raise the possibility that TAVI may not provide uniform improvements in aspects of daily functioning. In general, the lack of clarity over findings with respect to generic QOL is conspicuous and does not parallel what has been reported for heart failure specific QOL measures.

This prospective study extends beyond previous reports in two ways, firstly by comparing major morbidity outcomes and QOL outcomes among an Australian cohort of TAVI and AVR patients. By comparison to international experiences, there is little data from Australia where transcatheter aortic valves are only approved for use in patients deemed either inoperable or high-risk for AVR by a heart team. A second unique aspect of the current study is that we sought to determine the extent to which there is clinically significant change in generic QOL 6-months after TAVI by comparison to AVR taking into consideration operability, which has not been reported previously.

2. Methods {#s2}
==========

2.1. Patients {#s2a}
-------------

Consecutive patients undergoing TAVI or isolated AVR at Flinders Medical Centre, South Australia, Australia, from February 2010 to July 2013 were eligible for the study. To make comparable TAVI and AVR groups exclusion criteria was EuroSCORE \< 6 and age \< 75 years. A flow chart of participants through the study is shown in [Figure 1](#jgc-12-01-030-g001){ref-type="fig"}. From 146 eligible patients, 26 were not approached for consent because of not attending pre-admission clinic or being an urgent procedure. Total 77 completed baseline QOL assessment and 75 completed six-month follow-up assessment. Medical data was collected prospectively according to standardized definitions,[@b20] and ethics approval was granted (Approval Number 148.13).

![Flow chart of patients through the study.\
AVR: aortic valve replacement; QOL: quality of life; TAVI: transcatheter aortic valve implantation.](jgc-12-01-030-g001){#jgc-12-01-030-g001}

2.2. TAVI patient selection {#s2b}
---------------------------

The process for TAVI is described elsewhere.[@b21],[@b22] Briefly, transcatheter aortic valves are not commercially available in Australia and are implanted in patients deemed either inoperable or high-risk for AVR by a heart team (comprising at least one cardiac surgeon and at least one interventional cardiologist) or as part of a clinical trial. Patients with severe aortic stenosis referred for intervention were assessed by the heart team, taking into consideration age, comorbidities, risk scores and frailty. Patients were classified as being suitable for either open AVR or TAVI or as inoperable and only suitable for the TAVI procedure. A clinical decision was made whether the individual proceeded to AVR or TAVI.

2.3. TAVI technique {#s2c}
-------------------

All transcatheter valve procedures were performed by an experienced interventional cardiologist and cardiac surgeon in the catheterization laboratory using combined fluoroscopy and transesophegeal echocardiography (TEE) guidance. All patients had a general anesthetic and femoral vascular access. Procedures in which successful deployment was achieved utilized either the Edwards Sapien^®^ (Edwards Lifesciences, Irvine CA, *n* = 31) or Edwards Sapien XT^®^ (Edwards Lifesciences, Irvine CA, *n* = 45) prosthesis deployed either transfemoral (*n* = 70), transapical (*n* = 5), or transaortic (*n* = 1) approach utilizing rapid ventricular pacing. In the cohort, a failed procedure was defined as a procedure in which a valve was not successfully deployed or abandoned prior to valve deployment for technical and procedural limitations (*n* = 4).

2.4. AVR technique {#s2d}
------------------

All AVR procedures were performed by one of four experienced cardiothoracic surgeons. The technique was similar between surgeons. Access was via standard median sternotomy. Cardiopulmonary bypass was established using aortic and right atrial cannulation with arrest achieved by high dose tepid blood cardioplegia delivered in an antegrade fashion. Four different tissue valve prostheses were used; two porcine (Medtronic Mosaic^®^, Medtronic Inc. Minneapolis MN; St Jude Medical Epic^®^, St Jude Medical Inc. Minneapolis MN), two pericardial (St Jude Medical Trifecta^®^, St Jude Medical Inc. Minneapolis MN; Edwards Perimount Magna^®^, Edwards Lifesciences, Irvine CA). No patient received a mechanical prosthesis. Intra-operative TEE was used as needed.

2.5. Morbidity endpoints {#s2e}
------------------------

Postoperative morbidity and mortality were defined consistent with the Society of Thoracic Surgeons database [@b23] and included: (a) mortality during the index hospitalisation or within 30 days of surgery regardless of location; (b) neurological injury (permanent stroke, cerebrovascular accident or central neurological deficit persisting for longer than 72 h); (c) renal failure (new requirement for renal dialysis or increase in serum creatinine to more than 2.0 mg/dL and double the most recent preoperative creatinine level); (d) prolonged ventilation (\> 24 h postoperatively); (e) reoperation procedure or intervention for any reason during the index admission; or (f) postoperative myocardial infarction (MI) (two or more of cardiac enzyme level elevation, presence of new wall motion abnormality on echocardiography, or presence of new Q waves on ECG). In addition, we assessed the units of red blood cells transfused.

2.6. QOL and depression symptoms {#s2f}
--------------------------------

Assessments were performed in the week prior to procedure and at six-month follow-up using the QOL Short Form-12 (SF-12) that covers eight general QOL domains with good validity in cardiac populations.[@b19], [@b24] Depression symptoms were measured at 30-days and 6-months with the Patient health questionnaire (PHQ-9) as recommended elsewhere.[@b25] PHQ-9 scores ≥ 10 have favorable psychometric validity to identify depression in cardiac patients including cardiac surgery patients.[@b26],[@b27]

2.7. Statistical analysis {#s2g}
-------------------------

Statistical analyses were performed with SPSS^®^ 20.0 (SPSS Inc., Chicago, IL). In all analyses, *P* ≤ 0.05 was considered significant and no adjustment was made for multiple comparisons.[@b28] Values are expressed as mean ± SD or median \[interquartile range (IQR), 25% to 75%\]. Descriptive comparisons were made with the General Linear Model, chi-square statistic with Fishers exact test, or Mann-Whitney test. Individual QOL domains were analyzed with analysis of covariance (ANCOVA). Three models were run with incremental adjustment for preoperative QOL domain (Model 1), preoperative QOL domain and EuroSCORE (Model 2), and preoperative QOL domain, EuroSCORE and operability (Model 3). Ancillary analysis of clinically significant deterioration was based on the a priori moderate effect size (effect size change -- 0.50) [@b29] and calculated as; ΔQOL~Time2~ − QOL~Time1~ / SD QOL~Time1~. With respect to depression symptoms, analysis examined rates of clinically significant depressive symptoms between groups (i.e., PHQ ≥ 5 and ≥ 10) with the chi-square statistic.

3. Results {#s3}
==========

3.1. Descriptive comparisons {#s3a}
----------------------------

Descriptive comparisons between groups are shown in [Table 1](#jgc-12-01-030-t01){ref-type="table"}. TAVI patients were older, spent less time in hospital post-procedure, and were characterized by a lower proportion of operable patients, patients with previous valvuloplasty, lung disease, higher chronic kidney disease (CKD) staging and higher NYHA class. Patients lost follow-up were characterized by a higher proportion of peripheral vascular disease (26.1% *vs*. 9.1%, *P* = 0.006) and larger BSA (1.94 ± 0.24 *vs*. 1.92 ± 0.27) but were otherwise similar.

3.2. Short-term morbidity and mortality {#s3b}
---------------------------------------

In general, TAVI patients did not experience disproportionate incident morbidity or mortality ([Table 2](#jgc-12-01-030-t02){ref-type="table"}). The renal failure/dialysis endpoint tended to be higher among the TAVI group (TAVI 5.0% *vs*. AVR 0%, *P* = 0.06). Prolonged ventilation was higher among the AVR group (TAVI 11.9% *vs*. AVR 20.6%, *P* = .004) and AVR group also required more transfused units of red blood cells \[TAVI 0 (0--1) *vs*. AVR 2 (0--3), *P* = 0.01\]. Otherwise TAVI patients experienced comparable rates of incident MI and requirement for reoperation.

###### Descriptive comparisons by procedure group.

                                      Total *n* = 146    AVR *n* = 66    TAVI *n* = 80     *P*
  ---------------------------------- ----------------- ---------------- --------------- ----------
  Age, yrs                             83.31 ± 4.62      81.14 ± 3.53    85.10 ± 4.67    \< 0.001
  Male                                   76 (52.1)        29 (43.9)        47 (58.8)       0.08
  Operability                           107 (73.3)        66 (100.0)       41 (51.2)     \< 0.001
  Logistic EuroSCORE, median IQR       12.0 (8--18)     10.5 (7--15.5)    13 (9--19)       0.08
  Body surface area                     1.93 ± 0.25      1.95 ± 0.21      1.91 ± 0.28      0.32
  CKD                                    21 (14.4)         6 (9.1)         15 (18.8)       0.10
   Stage 1                               15 (10.3)        11 (16.7)          4 (5)      
   Stage 2                               60 (41.1)        30 (45.5)        30 (37.5)    
   Stage 3                               60 (41.1)        22 (33.3)        38 (47.5)    
   Stage 4                                8 (5.5)          3 (4.5)          5 (6.2)     
   Stage 5                                3 (2.1)             0             3 (3.8)     
  Atrial fibrillation                    43 (29.5)        17 (25.8)        26 (29.5)       0.37
  Diabetes                               46 (31.5)        22 (33.3)        24 (30.0)       0.67
  Redo                                   44 (30.1)         4 (6.1)         40 (50.0)     \< 0.001
  Previous valvuloplasty                 22 (15.1)         3 (4.5)         19 (23.8)     \< 0.001
  Peripheral vascular disease            25 (17.1)         7 (10.6)        18 (22.5)       0.06
  Lung disease                           56 (8.4)         19 (28.8)        37 (46.2)       0.03
  Cerebrovascular disease                 (22.6)          14 (21.2)        19 (2.8)        0.72
  Hypertension                          122 (83.6)        54 (81.8)        68 (85.0)       0.61
  Hypercholesterolemia                  116 (79.5)        49 (74.2)        67 (83.8)       0.16
  NYHA Class                            2.57 ± 0.86      2.41 ± 0.94      2.70 ± 0.77      0.04
  LVEF % \> 60                           93 (6.7)         43 (65.2)        50 (62.5)       0.82
   45-- 60                               30 (20.5)        13 (19.7)        17 (21.2)    
   30--45                                16 (11.0)         6 (9.1)         10 (12.5)    
   \< 30                                  7 (4.8)          4 (6.1)           (3.8)      
  Hospital stay (days), median IQR       7 (5--9)        8 (6--10.5)       6 (4--9)        0.04

Data presented as mean ± SD or *n* (%) unless otherwise stated. Groups inclusive of aborted procedures. AVR: aortic valve replacement; CKD: chronic kidney disease; IQR: interquartile range; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; TAVI: transcatheter aortic valve implantation.

###### In-hospital morbidity by procedure group.

  Incident morbidity\*          Total *n* = 146   AVR *n* = 66   TAVI *n* = 80    *P*
  ---------------------------- ----------------- -------------- --------------- -------
  Mortality \< 30 days              6 (4.1)         3 (4.5)         3 (3.8)       1.0
  Stroke, CVA                       5 (3.4)         2 (3.0)         3 (3.8)       1.0
  New renal failure/dialysis        4 (2.7)            \-           4 (5.0)      0.06
  Ventilation \> 24 h              17 (11.9)       13 (20.6)        4 (5.0)      0.004
  Reoperation                       3 (2.1)         2 (3.0)         1 (1.3)      0.71
  Myocardial infarction             5 (3.4)         3 (4.5)         2 (2.5)      0.66
  Combined endpoint (binary)       36 (24.7)       20 (30.3)       16 (20.0)     0.15
  RBC transfused, median IQR       2 (0--2)         2 (0--3)       0 (0--1)      0.01
  Aborted procedure^\#^             4 (2.7)            \-        4 (5.0)*^\#^*   0.13

Data presented as mean ± SD or *n* (%) unless otherwise stated. \*Society of Thoracic Surgeons definitions were used; ^\#^Aborted procedures. 1: bleeding and haematoma following heparinzation; 2: unable to deploy catheter system due to sheath kinking; 3: balloon valvuloplasty performed, valve not deployed; 4: left coronary artery occluded with balloon valvuloplasty, valve not deployed. AVR: aortic valve replacement; CVA: cerebrovascular accident; IQR: interquartile range; RBC: red blood cells; TAVI: transcatheter aortic valve implantation.

3.3. QOL and depression symptoms {#s3c}
--------------------------------

Analysis of mean NYHA class showed significant improvement in symptoms for both TAVI and surgical AVR patients following surgery (*P* \< 0.001), however there were no differences between groups at six months ([Table 3](#jgc-12-01-030-t03){ref-type="table"}). Sensitivity and unadjusted analysis according to categorical NYHA class corroborated that there were no differences between groups at six-months (*P* = 0.75). Comparison of generic QOL showed that TAVI patients were found to report, on average, comparable QOL at six month follow-up in most SF-12 domains (all *P* \> 0.20). Only vitality was significantly higher after AVR after adjustment for EuroSCORE (*P* = 0.01) though the finding was no longer significant after adjustment for operability (*P* = 0.10). Analyses showed moderate effect size partial *η*^2^ = 0.13.

As shown in [Table 4](#jgc-12-01-030-t04){ref-type="table"}, clinically significant improvement was common in all QOL domains with nearly 50% of patients improving in bodily pain, social functioning and emotional role. By contrast, one in every six patients experienced deterioration in vitality, mental health, bodily pain and social functioning (range: 17.3%--33.3%). Unadjusted analysis for trend suggested that there were no differences between TAVI and AVR patients (all *P* \> 0.05). There was no significant difference between groups in mild to moderate depressive symptoms at either 30-days and 6 months (*P* \> 0.20).

###### Quality of life at six months by procedure group^§^.

  ---------------------------------------------------------------------------------------------
  QOL domain               AVR\            TAVI\       Model 1\*\   Model 2^\#^\   Model 3^†^\
                         *n* = 35        *n* = 40         *P*           *P*            *P*
  ------------------- --------------- --------------- ------------ -------------- -------------
  NHYA class                                                                      

   Preoperative         2.49 ± 1.01     2.55 ± 0.90                               

   Six-months           1.60 ± 1.04     1.67 ± 1.05       0.79          0.82          0.86

  Physical function                                                               

   Preoperative        27.86 ± 2.52    15.00 ± 25.19                              

   Six-months          40.00 ± 37.96   28.25 ± 29.56      0.56          0.63          0.91

  Vitality                                                                        

   Preoperative        32.86 ± 24.8    34.76 ± 26.97                              

   Six-months          47.14 ± 26.96   30.98 ± 25.64      0.01          0.01          0.26

  Physical role                                                                   

   Preoperative        33.21 ± 28.28   32.50 ± 29.66                              

   Six-months          57.93 ± 34.70   48.06 ± 29.41      0.37          0.41          0.41

  Bodily pain                                                                     

   Preoperative        72.86 ± 25.85   63.13 ± 31.21                              

   Six-months          83.14 ± 26.65   73.70 ± 33.88      0.24          0.91          0.51

  General health                                                                  

   Preoperative        55.00 ± 26.98   46.38 ± 26.14                              

   Six-months          55.57 ± 27.51   47.89 ± 23.53      0.60          0.68          0.61

  Mental health                                                                   

   Preoperative        44.28 ± 11.48   45.00 ± 9.72                               

   Six-months          42.50 ± 11.42   45.48 ± 14.84      0.40          0.50          0.75

  Emotional role                                                                  

   Preoperative        54.29 ± 34.02   59.38 ± 33.22                              

   Six-months          78.21 ± 26.1    73.80 ± 28.42      0.45          0.42          0.76

  Social function                                                                 

   Preoperative        58.57 ± 33.73   56.25 ± 35.25                              

   Six-months          77.14 ± 28.03   75.03 ± 33.01      0.81          0.70          0.25
  ---------------------------------------------------------------------------------------------

Data presented as mean ± SD. \*Model 1 adjusted for baseline SF-12 score; ^\#^Model 2 adjusted for baseline score + EuroSCORE; ^†^Model 3 adjusted for adjusted for baseline score + EuroSCORE + operability; ^§^ANCOVA analysis on square root transformations; backtransformed scores shown. AVR: aortic valve replacement; NYHA: New York Heart Association; QOL: quality of life; SF-12: short form-12; TAVI: transcatheter aortic valve implantation.

###### Deterioration and improvement in six-month QOL by procedure group.

                       AVR, *n* = 35   TAVI, *n* = 40      *P*                 
  ------------------- --------------- ---------------- ----------- ----------- ------
  General health         9 (25.7)        12 (34.3)      9 (22.5)    10 (25.0)   0.27
  Physical function      6 (17.1)        15 (42.9)      5 (12.5)    16 (40.0)   0.63
  Vitality               5 (14.3)        16 (45.7)      16 (40.0)   13 (32.5)   0.97
  Physical role          5 (14.3)        22 (62.9)      4 (10.0)    18 (45.0)   0.06
  Mental health          16 (45.7)        9 (25.7)      10 (25.0)   12 (30.0)   0.52
  Bodily pain            6 (17.1)        18 (51.4)      8 (20.0)    19 (47.5)   0.81
  Social function        6 (17.1)        19 (54.3)      7 (17.5)    18 (45.0)   0.38
  Emotional role         6 (17.1)        19 (54.3)      5 (12.5)    18 (45.0)   0.28

Data presented as *n* (%). AVR: aortic valve replacement; QOL: quality of life; TAVI: transcatheter aortic valve implantation; Clinically significant change effect sizes ≥ 0.50 and ≤ −0.50.

4. Discussion {#s4}
=============

The present study has shown that incident morbidity for MI, reoperation and combined morbidity endpoint was generally not significantly different in TAVI by comparison to AVR, corroborating international literature.[@b1]--[@b9] Comorbidity characteristics of TAVI patients by definition contribute to their high-risk or inoperable status, and TAVI patients were found to experience significantly higher incident renal failure supporting general short term findings,[@b10] yet perhaps diverging from documented improvements in estimated glomerular filtration rate after TAVI.[@b30] By contrast, AVR patients experienced a significantly higher proportion of prolonged ventilation and required more transfused red blood cells. It was evident here that operability attenuated differences in six-month QOL between groups. It was further evident that clinically significant improvement and deterioration in QOL was common in both groups. As our finding was based on a relatively small sample, further validation in larger samples will help answer the extent to which TAVI and AVR is associated with clinically significant improvement and deterioration in QOL.

This study adds to the international literature comparing TAVI and AVR by reporting Australian results where TAVI is approved only for inoperable or high-risk patients. The morbidity findings can be compared alongside international reports,[@b31] and others concerning Australian TAVI patients,[@b32],[@b33] and generally higher risk aortic stenosis patients. Here we found few differences in major morbidity outcomes delineated by the Society for Thoracic Surgeons.[@b23] This study also extends the extant literature which to date has been inconclusive with regards to TAVI impact on generic QOL predominantly because of the relative infancy of TAVI procedures. By contrast to survival, morbidity and heart failure, previous studies are less consistent regarding group differences in generic QOL.[@b34],[@b35] Previous TAVI studies have reported improvements in functional NYHA Class from as early as 30 days and sustained in 75% of patients at 2-year follow-up.[@b12]--[@b18] In terms of heart failure specific QOL, improvement in Minnesota Living With Heart Failure Questionnaire and Kansas City Cardiomyopathy Questionnaire was reported from 30 days to 1 year follow-up.[@b13],[@b17],[@b18] Here, it was evident that once adjustment was made for operability status there was no difference between TAVI and AVR patients with regards to average QOL at six months.

It was further evident that inspection of mean QOL alone may obscure clinically significant QOL improvement and deterioration. This approach to improvement and decline in QOL parallels what has been reported for neurocognitive deficits.[@b36] Though it was evident that there were no between group differences in QOL change in this sample, it was nevertheless noteworthy that one in every six patients experienced deterioration in general health, vitality, mental health, bodily pain and social functioning (range: 17.3%--33.3%). Yet, nearly 50% of all patients showed clinically significant improvements in bodily pain, social functioning and emotional role, thus contrasting to Krane *et al*\'s German TAVI cohort.[@b14] The latter finding is important to contextualize in terms of the inoperable status of Australian TAVI patients and the direct comparison to AVR patients.

The strengths of this study included selection of older high-risk patients in a contemporary dataset and use of advanced statistical analyses to determine the effects of operability, and also clinically significant change in QOL. The practical implications of this study include informing clinical decision making and rehabilitation practices for elderly aortic stenosis patients.[@b24] Similarly, the failure to make QOL gains,[@b14],[@b18],[@b35] may provide valuable information to aid patients\' decision making, considering that QOL is salient to patients.[@b19]

These findings are presented with several limitations that may temper the generalizability including small sample size and recruitment from a single surgical centre. Moreover, the study is based on early experience with first and second generation TAVI devices performed under general anaesthetic, whereas some centres insert second generation devices under local anaesthetic without transthoracic echocardiography guidance. The surgical centre also provides service from a broad geographical region inclusive of remote patients yet accessibility to postoperative services was not included in these analyses which may affect long term outcomes.[@b37],[@b38] The analysis of incident morbidity was constrained by few endpoints as reflected in the width of the confidence intervals. It is possible that selection bias at six month follow-up may overestimate QOL benefits of either TAVI or AVR. Also we opted not to utilize SF-12 QOL summary scores as they may not be sensitive to discrete effects for individual and heterogeneous QOL domains. Finally, the methodology to determine clinically significant change in QOL needs to be considered among other statistical methods as there is no universal agreement as to the best approach.

In conclusion, we observed clinically significant improvement and deterioration in six month QOL among high risk elderly aortic valve replacement patients. However overall QOL, and morbidity did not differ between TAVI and AVR once operability was taken into consideration.
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